These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 3755713

  • 1. Experimental pharmacokinetics of RSU-1069 and its analogues: high tumor/plasma ratios.
    Deacon JM, Holliday SB, Ahmed I, Jenkins TC.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1087-90. PubMed ID: 3755713
    [Abstract] [Full Text] [Related]

  • 2. High uptake of RSU 1069 and its analogues melanotic melanomas.
    Walling JM, Deacon J, Holliday S, Stratford IJ.
    Cancer Chemother Pharmacol; 1989 Jul; 24(1):28-32. PubMed ID: 2541936
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.
    Walton MI, Workman P.
    Cancer Chemother Pharmacol; 1988 Jul; 22(4):275-81. PubMed ID: 3168141
    [Abstract] [Full Text] [Related]

  • 4. Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069.
    Workman P, Walton MI.
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1307-10. PubMed ID: 6547936
    [Abstract] [Full Text] [Related]

  • 5. RSU 1069, a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitizer in vitro and in vivo.
    Adams GE, Ahmed I, Sheldon PW, Stratford IJ.
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1653-6. PubMed ID: 6548211
    [Abstract] [Full Text] [Related]

  • 6. Dual-function radiation sensitizers and bioreductive drugs: factors affecting cellular uptake and sensitizing efficiency in analogues of RSU 1069.
    Walling J, Stratford IJ, Adams GE, Stephens MA.
    Int J Radiat Biol Relat Stud Phys Chem Med; 1988 Apr; 53(4):641-9. PubMed ID: 3258298
    [Abstract] [Full Text] [Related]

  • 7. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
    Cole S, Stratford IJ, Adams GE, Fielden EM, Jenkins TC.
    Radiat Res; 1990 Oct; 124(1 Suppl):S38-43. PubMed ID: 2236508
    [Abstract] [Full Text] [Related]

  • 8. Studies on the mechanisms of the radiosensitizing and cytotoxic properties of RSU-1069 and its analogues.
    Walling JM, Stratford IJ, Adams GE, Silver AR, Ahmed I, Jenkins TC, Fielden EM.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1083-6. PubMed ID: 3755712
    [Abstract] [Full Text] [Related]

  • 9. A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitiser RSU-1069.
    Horwich A, Holliday SB, Deacon JM, Peckham MJ.
    Br J Radiol; 1986 Dec; 59(708):1238-40. PubMed ID: 3542110
    [No Abstract] [Full Text] [Related]

  • 10. The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor.
    Chaplin DJ, Durand RE, Stratford IJ, Jenkins TC.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1091-5. PubMed ID: 3755714
    [Abstract] [Full Text] [Related]

  • 11. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
    Cole S, Stratford IJ, Bowler J, Nolan J, Wright EG, Lorimore SA, Adams GE.
    Int J Radiat Oncol Biol Phys; 1991 Jul; 21(2):387-95. PubMed ID: 2061115
    [Abstract] [Full Text] [Related]

  • 12. Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivo.
    Ahmed I, Jenkins TC, Walling JM, Stratford IJ, Sheldon PW, Adams GE, Fielden EM.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1079-81. PubMed ID: 3755711
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
    Binger M, Workman P.
    Cancer Chemother Pharmacol; 1991 Jul; 29(1):37-47. PubMed ID: 1742848
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Oncogenic transforming potential of nitroimidazole radiosensitizers.
    Hall EJ, Hei TK.
    Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1231-4. PubMed ID: 2523882
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
    Cole S, Stratford IJ, Fielden EM, Adams GE, Leopold W, Elliott W, Suto M, Sebolt-Leopold J.
    Int J Radiat Oncol Biol Phys; 1992 May; 22(3):545-8. PubMed ID: 1735694
    [Abstract] [Full Text] [Related]

  • 19. The phosphate-group of DNA as a potential target for RSU-1069, a nitroimidazole-aziridine radiosensitizer.
    Silver AR, O'Neill P, Jenkins TC, McNeil SS.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1203-6. PubMed ID: 3755715
    [Abstract] [Full Text] [Related]

  • 20. Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice.
    Kanclerz A, Chapman JD.
    Int J Radiat Oncol Biol Phys; 1988 Feb; 14(2):309-16. PubMed ID: 2828290
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.